[A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].

Abstract

A 43-year-old female underwent muscle preserving mastectomy with 6 cycles of adjuvant CMF chemotherapy for breast cancer. She developed multiple lung metastases 16 months later. The metastases were refractory to 3 cycles of CAF administration, and worsened (PD). We therefore added high-dose toremifene to her treatment. This combination therapy brought a marked decrease in the lung metastases. After 9 cycles of CAF with high-dose toremifene therapy, lung metastatic findings had almost disappeared from her chest X-ray. Following this treatment, UFT and toremifene were orally administered for maintenance therapy. Thirty-two months later at present, no increase in these lesions has been observed. High-dose antiestrogen drugs have the potential to inhibit P-glycoprotein. The combination of high-dose toremifene with CAF is potentially effective against ADM-resistant breast cancer.

• Authors: M Kusama, H Kaise, S Nakayama, D Ohta, T Aoki, Y Koyanagi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 26 Issue 8 Pg. 1171-5 (Jul 1999) ISSN: 0385-0684 [Print] Japan
• PMID: 10431584 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Estrogen Antagonists
• Toremifene
• Doxorubicin
• Cyclophosphamide
• Fluorouracil

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Breast Neoplasms (pathology)
• Chemotherapy, Adjuvant
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Resistance, Neoplasm
• Estrogen Antagonists (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Mastectomy
• Toremifene (administration & dosage)